n-Lorem Foundation

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, n-Lorem Foundation sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting early-phase tilt top decile by trial count

n-Lorem Foundation: 12 sponsored US clinical trials, none currently recruiting.

n-Lorem Foundation sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Amyotrophic Lateral Sclerosis, with 3 trials.

Top-decile sponsor footprint

n-Lorem Foundation ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

12 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation

NCT07221760
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy

NCT07177196
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation

NCT07197268
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)

NCT06816498
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA)

NCT07197294
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene Mutation

NCT07588581
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

NCT07095712
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation

NCT07084311
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

NCT06977451
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

NCT06392126
ACTIVE NOT RECRUITING Phase 1

Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene Mutation

NCT06706388
NOT YET RECRUITING Phase 1

Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)

NCT07423494

Phase Distribution

PhaseTrial count
Phase 1 12

Therapeutic Areas

Amyotrophic Lateral Sclerosis 3
Dentatorubral-Pallidoluysian Atrophy 2
Autosomal Dominant Leukodystrophy 1
Neurodevelopmental Disorder With or Without Variable Brain Abnormalities 1
Bainbridge-Ropers Syndrome 1
Retinal Dystrophy 1

How the n-Lorem Foundation early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open).

Phase mix: 0 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Amyotrophic Lateral Sclerosis (3 trials), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

n-Lorem Foundation: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

n-Lorem Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share n-Lorem FoundationAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
n-Lorem Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

n-Lorem Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this n-Lorem Foundation page

12 registered trials is a research-attention snapshot, not an endorsement of n-Lorem Foundation or any single study.

  • None of n-Lorem Foundation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Amyotrophic Lateral Sclerosis is the condition n-Lorem Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Amyotrophic Lateral Sclerosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

n-Lorem Foundation pipeline card: 12 registered trials from official public datasets.Report a data error.